Answers are grounded in this paper and cite their sources.
Observational study reveals elevated serum PYGL in hepatitis E-induced acute liver failure, indicating high predictive value for 30-day mortality.
Hepatitis E virus (HEV) is a significant cause of acute liver failure (ALF). The role of glycogen phosphorylase L (PYGL) in the diagnosis and prognosis of HEV‐ALF remains unclear. This study collected clinical data and baseline characteristics from HEV‐ALF patients, acute hepatitis E (AHE) patients, and healthy controls (HCs), measuring serum PYGL levels in each group. Methods including Orthogonal partial least squares discriminant analysis (OPLS‐DA), receiver operating characteristic (ROC) and decision curve analysis (DCA) were used to evaluate the clinical utility of PYGL. Results showed that PYGL effectively diagnosed HEV‐ALF (AUC = 0.911). PYGL levels were significantly higher in HEV‐ALF patients than in AHE patients and HCs ( p < 0.001). Among HEV‐ALF patients, non‐survivors exhibited higher PYGL levels than survivors ( p < 0.001). PYGL demonstrated good predictive ability for 30‐day mortality (AUC = 0.859). OPLS‐DA and DCA confirmed its strong decision‐making utility. Furthermore, PYGL levels escalated with increasing organ failure and paralleled clinical worsening, being highest in the deterioration group ( p < 0.05). PYGL is a potential diagnostic and prognostic biomarker in HEV‐ALF patients, where elevated levels indicate poorer outcomes and support early intervention.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: